Endocrine Abstracts

Case history: 58 year old male presented in April 2016 with haematemesis. Octreotide-avid pancreatic mass with liver metastases was identified. Liver biopsy demonstrated well differentiated Grade 2 NET (Ki-67 10–13%). He progressed on Somatostatin analogue therapy, and subsequently Sunitinib, following which he underwent four cycles of Peptide Receptor Radionuclide Therapy (PRRT) with partial response. In May 2018, there was radiological progression. He reported episodes ...

Section 1: Case history: 75 year old female diagnosed with Grade 1 pNET (Ki-67 index 70%) in 2018. Treated with subtotal pancreatectomy but 8 months post-surgery a follow up scan showed new liver metastases, at which point she was commenced on lanreotide. 3 months later she presented with an 8 week history of episodic weakness, sweating and confusion consistent with hypoglycaemia. These episodes initially improved with eating but had become more severe and unresponsive to carb...

Background: Everolimus, a mammalian target of rapamycin inhibitor, is licensed for use in adult pts with advanced well-differentiated pNETs in the UK. Limited Health-Related Quality-of-Life (HrQOL) data are available for everolimus therapy in these pts.Methods: This prospective study assessed changes in HrQoL (by monthly patient-reported EORTC QLQ-C30, -G.I.NET21 and EQ-5D questionnaires), in pts with pNETs during the first 6 months (mo) of treatment wit...